Home | Welcome to Contract Pharma   
Last Updated Saturday, November 22 2014
Print

Orphan Drugs



Drugs developed for rare diseases and conditions which, in the U.S., affect fewer than 200,000 people or which, in the EU, affect five or fewer per 10,000 people. Because sales of orphan drugs are likely to be small compared to their development costs, pharmaceutical companies are awarded exclusive rights to market these medicines for a period of time (usually seven years) as an incentive to develop them and bring them to market.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On